The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Non-coding RNAs as drug targets
Open accessAbstract
Most of the human genome encodes RNAs that do not code for proteins. These non-coding RNAs (ncRNAs) may affect normal gene expression and disease progression, making them a new class of targets for drug discovery. Because their mechanisms of action are often novel, developing drugs to target ncRNAs will involve equally novel challenges. However, many potential problems may already have been solved during the development of technologies to target mRNA. Here, we discuss the growing field of ncRNA — including microRNA, intronic RNA, repetitive RNA and long non-coding RNA — and assess the potential and challenges in their therapeutic exploitation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Landscape of transcription in human cells
Djebali, S., Davis, C. A., Merkel, A., Dobin, A., Lassmann, T., Mortazavi, A., Tanzer, A., Lagarde, J., Lin, W., Schlesinger, F., et al. (2012) · Nature · doi:10.1038/nature11233 · Cited by 5,187
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals
Guttman, M., Amit, I., Garber, M., French, C., Lin, M. F., Feldser, D., Huarte, M., Zuk, O., Carey, B. W., Cassady, J. P., et al. (2009) · Nature · doi:10.1038/nature07672 · Cited by 4,098
The Transcriptional Landscape of the Mammalian Genome
Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M. C., Maeda, N., Oyama, R., Ravasi, T., Lenhard, B., Wells, C., et al. (2005) · Science · doi:10.1126/science.1112014 · Cited by 3,499
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Khalil, A. M., Guttman, M., Huarte, M., Garber, M., Raj, A., Rivea Morales, D., Thomas, K., Presser, A., Bernstein, B. E., van Oudenaarden, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904715106 · Cited by 2,872
RNA Maps Reveal New RNA Classes and a Possible Function for Pervasive Transcription
Kapranov, P., Cheng, J., Dike, S., Nix, D. A., Duttagupta, R., Willingham, A. T., Stadler, P. F., Hertel, J., Hackermüller, J., Hofacker, I. L., et al. (2007) · Science · doi:10.1126/science.1138341 · Cited by 2,538
Tripathi, V., Ellis, J. D., Shen, Z., Song, D. Y., Pan, Q., Watt, A. T., Freier, S. M., Bennett, C. F., Sharma, A., Bubulya, P. A., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.011 · Cited by 2,219
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Ji, P., Diederichs, S., Wang, W., Böing, S., Metzger, R., Schneider, P. M., Tidow, N., Brandt, B., Buerger, H., Bulk, E., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206928 · Cited by 2,189
Towards a molecular understanding of microRNA-mediated gene silencing
Jonas, S., & Izaurralde, E. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3965 · Cited by 1,872
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Antisense Transcription in the Mammalian Transcriptome
Katayama, S., Tomaru, Y., Kasukawa, T., Waki, K., Nakanishi, M., Nakamura, M., Nishida, H., Yap, C. C., Suzuki, M., Kawai, J., et al. (2005) · Science · doi:10.1126/science.1112009 · Cited by 1,661
The Sequence of the Human Genome
Venter, J. C., Smith, H. O., & Adams, M. D. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.237016 · Cited by 1,648
Polycomb Proteins Targeted by a Short Repeat RNA to the Mouse X Chromosome
Zhao, J., Sun, B. K., Erwin, J. A., Song, J.-J., & Lee, J. T. (2008) · Science · doi:10.1126/science.1163045 · Cited by 1,579
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
Gutschner, T., Hämmerle, M., Eißmann, M., Hsu, J., Kim, Y., Hung, G., Revenko, A., Arun, G., Stentrup, M., Groß, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2850 · Cited by 1,415
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Morris, K. V., & Mattick, J. S. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3722 · Cited by 1,371
Hammond, S. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.001 · Cited by 1,284
Role of Histone H3 Lysine 27 Methylation in X Inactivation
Plath, K., Fang, J., Mlynarczyk-Evans, S. K., Cao, R., Worringer, K. A., Wang, H., de la Cruz, C. C., Otte, A. P., Panning, B., & Zhang, Y. (2003) · Science · doi:10.1126/science.1084274 · Cited by 1,195
The Landscape of long noncoding RNA classification
St. Laurent, G., Wahlestedt, C., & Kapranov, P. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.03.007 · Cited by 1,191
Molecular Mechanisms of RNA Interference
Wilson, R. C., & Doudna, J. A. (2013) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-083012-130404 · Cited by 1,076
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Noncoding RNA NORAD Regulates Genomic Stability by Sequestering PUMILIO Proteins
Lee, S., Kopp, F., Chang, T.-C., Sataluri, A., Chen, B., Sivakumar, S., Yu, H., Xie, Y., & Mendell, J. T. (2016) · Cell · doi:10.1016/j.cell.2015.12.017 · Cited by 897
The delivery of therapeutic oligonucleotides
Juliano, R. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw236 · Cited by 854
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Myotonic Dystrophy in Transgenic Mice Expressing an Expanded CUG Repeat
Mankodi, A., Logigian, E., Callahan, L., McClain, C., White, R., Henderson, D., Krym, M., & Thornton, C. A. (2000) · Science · doi:10.1126/science.289.5485.1769 · Cited by 737
Simon, J. A., & Kingston, R. E. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.02.013 · Cited by 733
The Long Noncoding RNAs NEAT1 and MALAT1 Bind Active Chromatin Sites
West, J. A., Davis, C. P., Sunwoo, H., Simon, M. D., Sadreyev, R. I., Wang, P. I., Tolstorukov, M. Y., & Kingston, R. E. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.07.012 · Cited by 709
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678
Modarresi, F., Faghihi, M. A., Lopez-Toledano, M. A., Fatemi, R. P., Magistri, M., Brothers, S. P., van der Brug, M. P., & Wahlestedt, C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2158 · Cited by 668
Widespread occurrence of antisense transcription in the human genome
Yelin, R., Dahary, D., Sorek, R., Levanon, E. Y., Goldstein, O., Shoshan, A., Diber, A., Biton, S., Tamir, Y., Khosravi, R., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt808 · Cited by 648
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophy
Chiriboga, C. A., Swoboda, K. J., Darras, B. T., Iannaccone, S. T., Montes, J., De Vivo, D. C., Norris, D. A., Bennett, C. F., & Bishop, K. M. (2016) · Neurology · doi:10.1212/wnl.0000000000002445 · Cited by 612
Bedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A. C., DeConti, R., Hersh, E. M., Hersey, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0483 · Cited by 600
Zhang, B., Arun, G., Mao, Y. S., Lazar, Z., Hung, G., Bhattacharjee, G., Xiao, X., Booth, C. J., Wu, J., Zhang, C., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.06.003 · Cited by 598
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss
Arun, G., Diermeier, S., Akerman, M., Chang, K.-C., Wilkinson, J. E., Hearn, S., Kim, Y., MacLeod, A. R., Krainer, A. R., Norton, L., et al. (2016) · Genes & Development · doi:10.1101/gad.270959.115 · Cited by 585
Melanoma addiction to the long non-coding RNA SAMMSON
Leucci, E., Vendramin, R., Spinazzi, M., Laurette, P., Fiers, M., Wouters, J., Radaelli, E., Eyckerman, S., Leonelli, C., Vanderheyden, K., et al. (2016) · Nature · doi:10.1038/nature17161 · Cited by 582
Circular RNAs: Identification, biogenesis and function
Ebbesen, K. K., Kjems, J., & Hansen, T. B. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.07.007 · Cited by 558
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
Targeting long non-coding RNA to therapeutically upregulate gene expression
Wahlestedt, C. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4018 · Cited by 532
Towards a therapy for Angelman syndrome by targeting a long non-coding RNA
Meng, L., Ward, A. J., Chun, S., Bennett, C. F., Beaudet, A. L., & Rigo, F. (2015) · Nature · doi:10.1038/nature13975 · Cited by 518
Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E., & for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) · Annals of Neurology · doi:10.1002/ana.24555 · Cited by 518
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
Wheeler, T. M., Leger, A. J., Pandey, S. K., MacLeod, A. R., Nakamori, M., Cheng, S. H., Wentworth, B. M., Bennett, C. F., & Thornton, C. A. (2012) · Nature · doi:10.1038/nature11362 · Cited by 502
Engreitz, J. M., Sirokman, K., McDonel, P., Shishkin, A. A., Surka, C., Russell, P., Grossman, S. R., Chow, A. Y., Guttman, M., & Lander, E. S. (2014) · Cell · doi:10.1016/j.cell.2014.08.018 · Cited by 500
Repeat expansion disease: progress and puzzles in disease pathogenesis
La Spada, A. R., & Taylor, J. P. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2748 · Cited by 488
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Self-citationLennox, K. A., & Behlke, M. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1206 · Cited by 453
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Kuyumcu-Martinez, N. M., Wang, G.-S., & Cooper, T. A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.07.027 · Cited by 445
The Reality of Pervasive Transcription
Clark, M. B., Amaral, P. P., Schlesinger, F. J., Dinger, M. E., Taft, R. J., Rinn, J. L., Ponting, C. P., Stadler, P. F., Morris, K. V., Morillon, A., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1000625 · Cited by 440
Promiscuous RNA binding by Polycomb repressive complex 2
Davidovich, C., Zheng, L., Goodrich, K. J., & Cech, T. R. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2679 · Cited by 440
Most “Dark Matter” Transcripts Are Associated With Known Genes
van Bakel, H., Nislow, C., Blencowe, B. J., & Hughes, T. R. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000371 · Cited by 428
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426
Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75852 · Cited by 413
TGF-β–Induced Upregulation of malat1 Promotes Bladder Cancer Metastasis by Associating with suz12
Fan, Y., Shen, B., Tan, M., Mu, X., Qin, Y., Zhang, F., & Liu, Y. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1455 · Cited by 410
Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development
Eißmann, M., Gutschner, T., Hämmerle, M., Günther, S., Caudron-Herger, M., Groß, M., Schirmacher, P., Rippe, K., Braun, T., Zörnig, M., et al. (2012) · RNA Biology · doi:10.4161/rna.21089 · Cited by 395
Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J. E., Partridge, T. A., & Wilton, S. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.42 · Cited by 388
Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNA
Wheeler, T. M., Sobczak, K., Lueck, J. D., Osborne, R. J., Lin, X., Dirksen, R. T., & Thornton, C. A. (2009) · Science · doi:10.1126/science.1173110 · Cited by 387
Why the need for qPCR publication guidelines?—The case for MIQE
Bustin, S. A. (2010) · Methods · doi:10.1016/j.ymeth.2009.12.006 · Cited by 375
RNAi Factors Are Present and Active in Human Cell Nuclei
Gagnon, K. T., Li, L., Chu, Y., Janowski, B. A., & Corey, D. R. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.013 · Cited by 372
Self-citationMiravirsen (SPC3649) can inhibit the biogenesis of miR-122
Gebert, L. F. R., Rebhan, M. A. E., Crivelli, S. E. M., Denzler, R., Stoffel, M., & Hall, J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt852 · Cited by 364
Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., H⊘g, A., Worm, J., Hedtjärn, M., Souleimanian, N., Miller, P., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp841 · Cited by 360
Groh, M., Lufino, M. M. P., Wade-Martins, R., & Gromak, N. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004318 · Cited by 352
Malat1 is not an essential component of nuclear speckles in mice
Nakagawa, S., Ip, J. Y., Shioi, G., Tripathi, V., Zong, X., Hirose, T., & Prasanth, K. V. (2012) · RNA · doi:10.1261/rna.033217.112 · Cited by 350
Fogal, V., Richardson, A. D., Karmali, P. P., Scheffler, I. E., Smith, J. W., & Ruoslahti, E. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01101-09 · Cited by 329
Voit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., De Kimpe, S. J., Eagle, M., Guglieri, M., Hood, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70195-4 · Cited by 306
An imprinted antisense RNA overlaps UBE3A and a second maternally expressed transcript
Rougeulle, C., Cardoso, C., Fontés, M., Colleaux, L., & Lalande, M. (1998) · Nature Genetics · doi:10.1038/ng0598-15 · Cited by 298
The recruitment of chromatin modifiers by long noncoding RNAs: lessons from PRC2
Davidovich, C., & Cech, T. R. (2015) · RNA · doi:10.1261/rna.053918.115 · Cited by 295
Kimberling, W. J., Hildebrand, M. S., Shearer, A. E., Jensen, M. L., Halder, J. A., Trzupek, K., Cohn, E. S., Weleber, R. G., Stone, E. M., & Smith, R. J. H. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181e5afb8 · Cited by 270
Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications
Aartsma-Rus, A., & van Ommen, G.-J. B. (2007) · RNA · doi:10.1261/rna.653607 · Cited by 267
Rader, D. J., & Kastelein, J. J. P. (2014) · Circulation · doi:10.1161/circulationaha.113.001292 · Cited by 264
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy
Mulders, S. A. M., van den Broek, W. J. A. A., Wheeler, T. M., Croes, H. J. E., van Kuik-Romeijn, P., de Kimpe, S. J., Furling, D., Platenburg, G. J., Gourdon, G., Thornton, C. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905780106 · Cited by 257
Long non-coding RNAs: modulators of nuclear structure and function
Bergmann, J. H., & Spector, D. L. (2014) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.08.005 · Cited by 256
Agostini, M., & Knight, R. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1825 · Cited by 254
SATO-KUWABARA, Y., MELO, S. A., SOARES, F. A., & CALIN, G. A. (2015) · International Journal of Oncology · doi:10.3892/ijo.2014.2712 · Cited by 245
Angelman syndrome: review of clinical and molecular aspects
Bird, L. (2014) · The Application of Clinical Genetics · doi:10.2147/tacg.s57386 · Cited by 238
Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides
Sierakowska, H., Sambade, M. J., Agrawal, S., & Kole, R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.12840 · Cited by 236
Thakral, S., & Ghoshal, K. (2015) · Current Gene Therapy · doi:10.2174/1566523214666141224095610 · Cited by 235
Ottosen, S., Parsley, T. B., Yang, L., Zeh, K., van Doorn, L.-J., van der Veer, E., Raney, A. K., Hodges, M. R., & Patick, A. K. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04220-14 · Cited by 230
Lentz, J. J., Jodelka, F. M., Hinrich, A. J., McCaffrey, K. E., Farris, H. E., Spalitta, M. J., Bazan, N. G., Duelli, D. M., Rigo, F., & Hastings, M. L. (2013) · Nature Medicine · doi:10.1038/nm.3106 · Cited by 229
Gagnon, K. T., Li, L., Janowski, B. A., & Corey, D. R. (2014) · Nature Protocols · doi:10.1038/nprot.2014.135 · Cited by 223
Self-citationMALAT1 long non-coding RNA in cancer
Yoshimoto, R., Mayeda, A., Yoshida, M., & Nakagawa, S. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.09.012 · Cited by 222
Promoter RNA links transcriptional regulation of inflammatory pathway genes
Matsui, M., Chu, Y., Zhang, H., Gagnon, K. T., Shaikh, S., Kuchimanchi, S., Manoharan, M., Corey, D. R., & Janowski, B. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt777 · Cited by 220
Self-citationDisease-associated repeat instability and mismatch repair
Schmidt, M. H. M., & Pearson, C. E. (2016) · DNA Repair · doi:10.1016/j.dnarep.2015.11.008 · Cited by 208
Haché, M., Swoboda, K. J., Sethna, N., Farrow-Gillespie, A., Khandji, A., Xia, S., & Bishop, K. M. (2016) · Journal of Child Neurology · doi:10.1177/0883073815627882 · Cited by 208
Toward a Consensus on the Binding Specificity and Promiscuity of PRC2 for RNA
Davidovich, C., Wang, X., Cifuentes-Rojas, C., Goodrich, K. J., Gooding, A. R., Lee, J. T., & Cech, T. R. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.017 · Cited by 204
Chamberlain, S. J., & Brannan, C. I. (2001) · Genomics · doi:10.1006/geno.2001.6543 · Cited by 204
Meng, L., Person, R. E., & Beaudet, A. L. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds130 · Cited by 202
The Unstable Repeats—Three Evolving Faces of Neurological Disease
Nelson, D. L., Orr, H. T., & Warren, S. T. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.022 · Cited by 202
Exon skipping therapy for Duchenne muscular dystrophy
Kole, R., & Krieg, A. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.008 · Cited by 192
The MicroRNA Biology of the Mammalian Nucleus
Roberts, T. C. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.40 · Cited by 189
CpG Still Rocks! Update on an Accidental Drug
Krieg, A. M. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0340 · Cited by 187
The experimental use of antisense oligonucleotides: a guide for the perplexed
Stein, C. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13885 · Cited by 183
Fomivirsen: Clinical Pharmacology and Potential Drug Interactions
Geary, R. S., Henry, S. P., & Grillone, L. R. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00002 · Cited by 160
van der Ree, M. H., van der Meer, A. J., van Nuenen, A. C., de Bruijne, J., Ottosen, S., Janssen, H. L., Kootstra, N. A., & Reesink, H. W. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13432 · Cited by 159
(2003) · Nature Cell Biology · doi:10.1038/ncb0603-490 · Cited by 153
Sarma, K., Levasseur, P. J., Aristarkhov, A., & Lee, J. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009785107 · Cited by 149
Cellular uptake and intracellular trafficking of oligonucleotides
Juliano, R. L., & Carver, K. A. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.005 · Cited by 149
Kaboli, P. J., Rahmat, A. B., Ismail, P., & Ling, K. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.015 · Cited by 140
Spinal muscular atrophy—recent therapeutic advances for an old challenge
Faravelli, I., Nizzardo, M., Comi, G. P., & Corti, S. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.77 · Cited by 138
Oligonucleotide therapeutic approaches for Huntington disease
Sah, D. W. Y., & D, N. A. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45130 · Cited by 137
Drug target miRNAs: chances and challenges
Schmidt, M. F. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.09.002 · Cited by 136
Nucleic acid-binding specificity of human FUS protein
Wang, X., Schwartz, J. C., & Cech, T. R. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv679 · Cited by 135
Pandey, S., Wheeler, T. M., Justice, S. L., Kim, A., Younis, H. S., Gattis, D., Jauvin, D., Puymirat, J., Swayze, E. E., Freier, S. M., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226969 · Cited by 131
RNA interference and double-stranded-RNA-activated pathways
Sledz, C. A., & Williams, B. R. G. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320952 · Cited by 122
An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies.
Mcclorey, G., & Wood, M. (2015) · Current opinion in pharmacology (Print) · doi:10.1016/j.coph.2015.07.005 · Cited by 121
Guided by RNAs: X-Inactivation as a Model for lncRNA Function
Froberg, J. E., Yang, L., & Lee, J. T. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.06.031 · Cited by 121
Oligonucleotide Therapeutics: Chemistry, Delivery and Clinical Progress
Sharma, V. K., & Watts, J. K. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.144 · Cited by 112
Off-targeting and other non-specific effects of RNAi experiments in mammalian cells.
Svoboda, P. (2007) · PubMed · Cited by 112
Therapeutic potential of antisense Bcl‐2 as a chemosensitizer for cancer therapy
Kim, R., Emi, M., Tanabe, K., & Toge, T. (2004) · Cancer · doi:10.1002/cncr.20696 · Cited by 109
Sensible use of antisense: how to use oligonucleotides as research tools
Myers, K. J., & Dean, N. M. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01420-0 · Cited by 105
Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing
Rigo, F., Hua, Y., Chun, S. J., Prakash, T. P., Krainer, A. R., & Bennett, C. F. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.939 · Cited by 104
A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications
Järver, P., O’Donovan, L., & Gait, M. J. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0454 · Cited by 102
Regulation of mammalian transcription and splicing by Nuclear RNAi
Kalantari, R., Chiang, C., & Corey, D. R. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1305 · Cited by 100
Self-citationOff‐Target Effects Related to the Phosphorothioate Modification of Nucleic Acids
Winkler, J., Stessl, M., Amartey, J., & Noe, C. R. (2010) · ChemMedChem · doi:10.1002/cmdc.201000156 · Cited by 96
Activating frataxin expression by repeat-targeted nucleic acids
Li, L., Matsui, M., & Corey, D. R. (2016) · Nature Communications · doi:10.1038/ncomms10606 · Cited by 94
Self-citationWhat Can We Learn From Clinical Trials of Exon Skipping for DMD?
Lu, Q., Çırak, S., & Partridge, T. A. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.6 · Cited by 92
Expanding the action of duplex RNAs into the nucleus: redirecting alternative splicing
Liu, J., Hu, J., & Corey, D. R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr780 · Cited by 91
Self-citationThe Increasing Urgency for Standards in Basic Biologic Research
Freedman, L. P., & Inglese, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0925 · Cited by 89
Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.
Rigo, F., Seth, P., & Bennett, C. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4939-1221-6_9 · Cited by 80
Digital Quantitation of Potential Therapeutic Target RNAs
Dodd, D. W., Gagnon, K. T., & Corey, D. R. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0427 · Cited by 79
Self-citationOligonucleotide-based strategies to combat polyglutamine diseases
Fiszer, A., & Krzyżosiak, W. J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku385 · Cited by 70
Keeping the biotechnology of antisense in context
Stein, C. A. (1999) · Nature Biotechnology · doi:10.1038/6909 · Cited by 68
Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells
Childs‐Disney, J. L., & Disney, M. D. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103910 · Cited by 67
Personalized gene silencing therapeutics for Huntington disease
Kay, C., Skotte, N. H., Southwell, A. L., & Hayden, M. R. (2014) · Clinical Genetics · doi:10.1111/cge.12385 · Cited by 54
Lai, J. C., Benimetskaya, L., Santella, R. M., Wang, Q., Miller, P. S., & Stein, C. A. (2003) · PubMed · Cited by 47
Anderson, E. M., Miller, P. S., Ilsley, D. D., Marshall, W., Khvorova, A., Stein, C. A., & Benimetskaya, L. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700901 · Cited by 42
Epigenetic-based therapies for Friedreich ataxia
Sandi, C., Sandi, M., Virmouni, S. A., Al-Mahdawi, S., & Pook, M. A. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00165 · Cited by 42
Functional annotation of the vlinc class of non-coding RNAs using systems biology approach
Laurent, G. S., Vyatkin, Y. V., Антонец, Д., Ri, M., Yao, Q., Saik, O., Shtokalo, D. N., de Hoon, M., Kawaji, H., Itoh, M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw162 · Cited by 42
Proof of Mechanism of Antisense Drugs
Crooke, S. T. (1996) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1996.6.145 · Cited by 42
Response to “The Reality of Pervasive Transcription”
van Bakel, H., Nislow, C., Blencowe, B. J., & Hughes, T. R. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001102 · Cited by 41
Chen, Z., Monia, B. P., & Corey, D. R. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025563v · Cited by 32
Self-citationRelative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma Cells
Benimetskaya, L., Lai, J. C. H., Khvorova, A., Wu, S., Hua, E., Miller, P. S., Zhang, L.-M., & Stein, C. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1294 · Cited by 32
&NA; (2007) · Drugs in R&D · doi:10.2165/00126839-200708050-00006 · Cited by 24
Bcl-2 Antisense in the Treatment of Human Malignancies: A Delusion in Targeted Therapy
Gjertsen, B. T., Bredholt, T., Ånensen, N., & Vintermyr, O. K. (2007) · Current Pharmaceutical Biotechnology · doi:10.2174/138920107783018381 · Cited by 21
Beg, M. S., Brenner, A. J., Sachdev, J. C., Ejadi, S., Borad, M. J., Kang, Y.-K., Lim, H. Y., Kim, T.-Y., Bader, A. G., Stoudemire, J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-c43 · Cited by 21
Evaluating the Mechanism of Action of Antiproliferative Antisense Drugs
Crooke, S. T. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.123 · Cited by 18
Meng, L., Ward, A. J., Bennett, C. F., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.nonrna15-ia28 · Cited by 5
Cited by
Long Noncoding RNA and Cancer: A New Paradigm
Bhan, A., Soleimani, M., & Mandal, S. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2634 · Cited by 2,861
Non-coding RNA networks in cancer
Anastasiadou, E., Jacob, L. S., & Slack, F. J. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.99 · Cited by 1,884
Non-coding RNAs in disease: from mechanisms to therapeutics
Nemeth, K., Bayraktar, R., Ferracin, M., & Calin, G. A. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-023-00662-1 · Cited by 885
Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Metadata
- Authors
- Matsui, M., & Corey, D. R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2016-07-22
- Volume
- 16
- Issue
- 3
- Pages
- 167-179
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2502698579
- Cited by
- 1,032
- References
- 144
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.